Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia.
Clinical Trial # E1912:
Ibrutnib and Rituximab vs standard FCR to prolong progression free survival of Chronic Lympocytic Leukemia or Small Lymphocytic Leukemia.
Participants muse be 18-70 years of age with a performance status of 0-2. The diagnosis of Chronic Lympocytic Leukemia or Small Lymphocytic Leukemia must be according to NCI/WCLL or SLL according to WHO criteria.
Exclusions include but are not limited to: Prior chemotherapy or monoclonal antibody therapy, major surgery within 28 days of registration, radiation therapy < 4 weeks prior to registration, recent Myocardial Infarction or Cerebrovascula Accident.
“You had such excellent speakers here that what they did for me was made me less afraid... so that if anything happened to me, I would know the processes to go through and what to ask for to benefit me as a person.”